Composition:

Each Goutifade 40 mg film coated tablet contains 40 mg of febuxostat.

Each Goutifade 80 mg film coated tablet contains 80 mg of febuxostat.

Indications:

Goutifade is a xanthine oxidase (XO) inhibitor indicated for the chromic management of hyperuricemia in adult patients with gout who have an inadequate response to a maximally titrated dose of allopurinol, who are intolerant to allopurinol, or for whom treatment with allopurinol is not advisable

For the safe and effective use of allopurinol, see allopurinol prescribing information.

Limitations of Use:

Goutifade is not recommended for the treatment of asymptomatic hyperuricemia

Approved by Egyptian Drug Authority: HF0294OA4548/102025 . Invalidation date: 20/10/2026

Kindly report any violated online promotional, educational and awareness material not having this message to The General administration for Regulation of Marketing & Advertising Materials at www.edaegypt.gov.eg”